Overview

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Status:
Withdrawn

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and best dose of rivogenlecleucel, and how well it works, in treating patients with blood cancer that has come back (recurrent) after stem cell transplant. Donor T-cell therapy (rivogenlecleucel) may help control transplant-related infections after stem cell transplant.

Phase:

Phase 1

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center
University of Washington

Collaborators:

Bellicum Pharmaceuticals
National Cancer Institute (NCI)